Biosimilaires des anticorps monoclonaux utilisés en thérapeutique
Les biosimilaires anti-TNF autorisés en Europe
DCI | Référence | Biosimilaires | Laboratoire |
---|---|---|---|
Adalimumab | Amgen | ||
AMSPARITY® | Pfizer | ||
Boehringer Ingelheim International | |||
Sandoz | |||
Sandoz | |||
Mylan | |||
Sandoz | |||
Fresenius | |||
Samsung Bioepis | |||
Amgen | |||
YUFLYMA® | Celltrion Healthcare | ||
Stada Arzneimittel AG | |||
Infliximab | Samsung Bioepis | ||
Hospira / Pfizer | |||
Celltrion Healthcare / Biogaran | |||
Sandoz | |||
Etanercept | Biogen France SAS | ||
Sandoz | |||
Pfizer | |||
NEPEXTO® | Mylan Ireland Limited |
Les biosimilaires anti-tumoraux autorisés en Europe
DCI | Référence | Biosimilaires | Laboratoire |
---|---|---|---|
Rituximab | Biogaran | ||
Celltrion Inc | |||
Celltrion Healthcare | |||
Sandoz | |||
Sandoz | |||
Celltrion Healthcare | |||
RUXIENCE® | Pfizer | ||
Trastuzumab | Celltrion Healthcare | ||
Amgen | |||
Samsung Bioepis | |||
Pfizer | |||
ZERCEPAC® | Accord Healthcare | ||
OGIVRI® | Mylan | ||
Bevacizumab | Amgen | ||
Pfizer | |||
EQUIDACENT® | Centus Biotherapeutics | ||
AYBINTIO® | Samsung Bioepis | ||
ONBEVZI® | Samsung Bioepis | ||
STADA Arzneimittel AG | |||
ALYMSYS® | Mabxience Research SL | ||
ABEVMY® | Mylan IRE Healthcare Limited |